Midatech Pharma (LON:MTPH) Announces Earnings Results

Midatech Pharma (LON:MTPH) announced its quarterly earnings results on Tuesday. The company reported GBX (1,000) (($12.73)) earnings per share for the quarter, Digital Look Earnings reports.

MTPH stock traded down GBX 1.10 ($0.01) on Tuesday, hitting GBX 18.90 ($0.24). The company’s stock had a trading volume of 147,173 shares, compared to its average volume of 61,863. The stock has a market cap of $7.85 million and a price-to-earnings ratio of -0.21. The company has a current ratio of 4.21, a quick ratio of 3.83 and a debt-to-equity ratio of 4.42. The firm has a 50 day moving average of GBX 31.81 and a two-hundred day moving average of GBX 16.26. Midatech Pharma has a 1 year low of GBX 2 ($0.03) and a 1 year high of GBX 79.90 ($1.02).

About Midatech Pharma

Midatech Pharma PLC, a specialty pharmaceutical company, focuses on developing and commercializing products in oncology and immunotherapy in the United States and the United Kingdom. The company operates through two segments, Pipeline Research and Development; and Commercial. Its products include Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; Gelclair, an oral gel barrier device indicated for the management and relief of pain due to oral mucositis; Oravig, an orally dissolving buccal tablet for oral thrush; and Soltamox, an oral liquid solution of tamoxifen citrate, for the treatment and prevention of breast cancer.

Featured Story: What are the qualifications of a portfolio manager?

Receive News & Ratings for Midatech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.